United States  

CytoDyn announces first site in the southeastern USA to enroll patients in Phase 2 coronavirus trial

Proactive Investors Wednesday, 8 April 2020
CytoDyn Inc (OTCQB:CYDY), the late stage biotech, said partner Novant Health has started enrolling patients in the company's Phase 2 randomized clinical trial using leronlimab for coronavirus (COVID-19) patients with mild-to-moderate symptoms. Novant Health is the second trial site in the USA and the first site in the southeastern US to initiate this Phase 2 trial. READ: CytoDyn collaborating with UK’s Department of Health to provide emergency access to leronlimab for critically ill coronavirus patients Earlier on Wednesday, it was reported that the death toll from the virus in the US now stands at nearly 13,000 and there were nearly 2,000 deaths between Tuesday and Wednesday. New York state alone recorded 731 deaths on Tuesday. "COVID-19 is the most significant health threat of our generation,” said Dr. Eric Eskioglu, executive vice president and chief medical officer at Novant Health in a statement. "We want to thank CytoDyn for partnering with us in this very important leronlimab clinical drug trial. With lives at risk, we are working together towards an effective treatment solution." "Based upon the results we have seen with several New York patients, we are hopeful that leronlimab can provide a benefit to patients throughout the country," added Nader Pourhassan, the president and CEO at CytoDyn The Novant Health network cares for around 5 million patients a year at nearly 700 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. A second trial this week CytoDyn is also initiating a second COVID-19 trial this week. This study is a Phase 2b/3 for severely ill COVID-19 patients and is for 342 patients, double-blinded with a 2:1 ratio (drug to placebo ratio). Patients enrolled in this trial are expected to be administered leronlimab for two weeks, with the primary endpoint being the mortality rate at 28 days and a secondary endpoint of mortality rate at 14 days. The company said it will perform an interim analysis on the data from 50 patients. Contact the author at [email protected]
0
shares
ShareTweetSavePostSend
 
Video Credit: CBS 2 New York - Published
News video: Coronavirus Update: Can Recovered Patients Still Spread COVID-19?

Coronavirus Update: Can Recovered Patients Still Spread COVID-19? 02:39

Many coronavirus patients who have recovered are going back to their jobs and reuniting with family, but some are still finding they're testing positive for traces of the virus. So can they still spread the disease? CBS2's Carolyn Gusoff reports.

You Might Like


Related videos from verified sources

Researchers ID Even More Symptoms Linked To Novel Coronavirus COVID-19 [Video]

Researchers ID Even More Symptoms Linked To Novel Coronavirus COVID-19

The US Centers for Disease Control and Prevention added six new symptoms to its list for the novel coronavirus COVID-19 last week. They include chills, repeated shaking with chills, muscle pain,..

Credit: Wochit     Duration: 00:40Published
Exclusive: Hospital Launches Clinical Trial After New York Doctor Touts Coronavirus Medication Cocktail [Video]

Exclusive: Hospital Launches Clinical Trial After New York Doctor Touts Coronavirus Medication Cocktail

One New York doctor claims to have kept hundreds of coronavirus patients out of the hospital with a cocktail of medications. It's been criticized as unproven, but now a major hospital in the area is..

Credit: CBS 2 New York     Duration: 03:23Published
Trump Administration Announces Effort To Fast-Track Coronavirus Vaccine Process [Video]

Trump Administration Announces Effort To Fast-Track Coronavirus Vaccine Process

The Trump Administration has announced "Operation Warp Speed," a massive effort to fast-track the process of getting a coronavirus vaccine; CBS2's Dr. Max Gomez reports.

Credit: CBS 2 New York     Duration: 02:08Published

Related news from verified sources

CytoDyn shares jump as it submits leronlimab license application to FDA; names Mulholland as interim finance chief

CytoDyn Inc (OTCQB:CYDY) said it reached a milestone Monday, namely its submission to the FDA of the final two parts required to license leronlimab as a...
Proactive Investors

CytoDyn Inc says five coronavirus patients able to go off oxygen after taking leronlimab; 12 treated so far in Phase 2 trial

CytoDyn Inc (OTCQB:CYDY), which has been utilizing its flagship drug candidate leronlimab as a treatment for the coronavirus (COVID-19), told investors Monday...
Proactive Investors